Tompkins Financial Corp Acquires 587 Shares of Danaher Co. (NYSE:DHR)

Tompkins Financial Corp raised its holdings in Danaher Co. (NYSE:DHR) by 1.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 34,780 shares of the conglomerate’s stock after acquiring an additional 587 shares during the quarter. Tompkins Financial Corp’s holdings in Danaher were worth $7,984,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Benjamin Edwards Inc. increased its stake in shares of Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after acquiring an additional 38 shares during the last quarter. Wedge Capital Management L L P NC increased its stake in Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 38 shares in the last quarter. Certified Advisory Corp raised its holdings in Danaher by 4.5% in the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock worth $231,000 after purchasing an additional 40 shares during the period. Meridian Financial Partners LLC boosted its position in shares of Danaher by 4.4% during the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after purchasing an additional 40 shares in the last quarter. Finally, Kovack Advisors Inc. grew its holdings in shares of Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after buying an additional 41 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 1.7 %

DHR stock opened at $241.94 on Friday. Danaher Co. has a twelve month low of $222.53 and a twelve month high of $281.70. The company has a market cap of $174.75 billion, a price-to-earnings ratio of 46.17, a P/E/G ratio of 4.23 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The business has a 50 day moving average price of $235.07 and a two-hundred day moving average price of $253.45.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the company earned $2.02 earnings per share. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. Analysts anticipate that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s dividend payout ratio is 20.61%.

Analyst Ratings Changes

DHR has been the topic of several recent analyst reports. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a report on Friday, December 13th. Raymond James decreased their price objective on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. TD Cowen raised their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Robert W. Baird reduced their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Finally, Guggenheim began coverage on shares of Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective on the stock. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.